Mydecine Innovations Group (STU:0NF0) Other Income (Expense) : €-2.56 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Mydecine Innovations Group Other Income (Expense)?

Mydecine Innovations Group's other income expense for the Mydecine Innovations Group's pretax income for the three months ended in Sep. 2024 was €0.03 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was €-2.56 Mil.

Mydecine Innovations Group Other Income (Expense) Historical Data

The historical data trend for Mydecine Innovations Group's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mydecine Innovations Group Other Income (Expense) Chart

Mydecine Innovations Group Annual Data

Trend

Aug14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Income (Expense)

Get a 7-Day Free Trial

-12.27

-9.78

-0.48

0.79

-6.90

Mydecine Innovations Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Income (Expense)	Get a 7-Day Free Trial															-0.02	-2.55	-0.03	-0.01	0.03

Mydecine Innovations Group Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.56 Mil.

Mydecine Innovations Group (STU:0NF0) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Mydecine Innovations Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mydecine Innovations Group Inc (STU:0NF0) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

MYCOF:USA MYCO:Canada

Address

1890 – 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9

Website

https://www.mydecine.com

Mydecine Innovations Group Inc is a biopharma and life sciences company engaged in the research, drug development, and clinical trials of psilocybin products.

Mydecine Innovations Group Headlines

No Headlines